Cardiology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
Clin Chem Lab Med. 2011 Sep 6;49(12):1937-48. doi: 10.1515/CCLM.2011.692.
Cardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury. In particular, the role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication.
心脏毒性是抗癌药物的严重不良反应，影响癌症患者的生活质量和总体生存。根据目前监测心脏功能的标准，只有在已经发生功能障碍时才会检测到心脏毒性，从而排除了预防其发展的任何机会。然而，在过去的十年中，出现了一种基于心脏生物标志物使用的新方法，并且已被证明是早期检测亚临床心脏损伤的有效替代策略。特别是肌钙蛋白 I 在识别有心脏毒性风险的患者以及血管紧张素转换酶抑制剂预防左心室射血分数降低和晚期心脏事件方面的作用，代表了预防这种并发症的有效工具。
